<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>continuous on KonFound-it!</title>
    <link>/tags/continuous/</link>
    <description>Recent content in continuous on KonFound-it!</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2020. All rights reserved.</copyright>
    <lastBuildDate>Wed, 13 May 2020 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="/tags/continuous/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>From early RCT: robust inference of Remdesivir effect on time to clinical improvement</title>
      <link>/2020/05/13/remdesivir-on-time-to-clinical-improvement/</link>
      <pubDate>Wed, 13 May 2020 00:00:00 +0000</pubDate>
      
      <guid>/2020/05/13/remdesivir-on-time-to-clinical-improvement/</guid>
      <description>Now consider the previous example of Remdesivir but instead we are interested in the continuous outcome variable of time to clinical improvement.
Figure 1. Time to clinical improvement in the Remdesivir example. Data from Table 3, Wang et al (2020).
 We can interpret the robustness of inference regarding Remdesivirâ€™s effect on time to clinical improvement in following ways.
Percent bias necessary to invalidate the inference To invalidate an inference, \(70.</description>
    </item>
    
  </channel>
</rss>